Abstract
Many non-cardiovascular drugs of common clinical use cause, as an unwanted accessory property, the prolongation of the cardiac repolarisation process, due to the block of the HERG (Human Ether-a-go-go Related Gene) potassium channel, responsible for the repolarising IKr current. This delayed cardiac repolarisation process can be often unmasked by a prolongation of the QT interval of the ECG. In these conditions, premature action potentials can generate morphologically anomalous after-polarisations, and trigger a dangerous kind of polymorphic ventricular tachyarrhythmia, known as torsade de pointes, which can evolve in ventricular fibrillation and death. The risk associated with the torsadogenic cardiotoxicity of drugs, which prolong the QT interval has been the topic of documents produced by many health authorities, giving important issues about the preclinical and clinical evaluation of cardiac safety. Besides, public and private research laboratories developed several experimental in vitro or in vivo strategies, aimed to an early recognition of the influence of a drug (or of a drugcandidate) on the HERG channel and / or on the cardiac repolarisation process. Also the identification of a possible pharmacophore model, common in all or at least in numerous torsadogenic drugs, could represent a first step for the development of useful in silico approaches, allowing a preliminary indication about the potential torsadogenic property of a given molecule. In this work, we described the electrophysiological basis of torsade de pointes and listed several pharmacological classes of torsadogenic drugs. Among them, we focused our attention on antipsychotics, with an accurate overview on the experimental and clinical reports about their torsadogenic properties. Moreover, a common structural feature exhibited by these drugs, despite of their remarkable chemical differences, is evidenced by a computational approach and is indicated as a possible “facilitating” requirement for their torsadogenic properties. Together with other remarks, coming from different computational studies, the individuation of a satisfactory “toxicophore” model could be greatly useful, for the theoretical prediction of torsadogenic properties of a given chemical moiety and for the design of new drugs devoid of such an undesired and potentially lethal side-effect.
Keywords: antipsychotic drugs, torsade de pointes, drug-induced arrhythmias, qt prolongation, cardiotoxicity, torsadogenic drugs
Current Medicinal Chemistry
Title: Torsadogenic Cardiotoxicity of Antipsychotic Drugs: a Structural Feature, Potentially Involved in the Interaction with Cardiac HERG Potassium Channels
Volume: 11 Issue: 20
Author(s): L. Testai, A. M. Bianucci, I. Massarelli, M. C. Breschi, E. Martinotti and V. Calderone
Affiliation:
Keywords: antipsychotic drugs, torsade de pointes, drug-induced arrhythmias, qt prolongation, cardiotoxicity, torsadogenic drugs
Abstract: Many non-cardiovascular drugs of common clinical use cause, as an unwanted accessory property, the prolongation of the cardiac repolarisation process, due to the block of the HERG (Human Ether-a-go-go Related Gene) potassium channel, responsible for the repolarising IKr current. This delayed cardiac repolarisation process can be often unmasked by a prolongation of the QT interval of the ECG. In these conditions, premature action potentials can generate morphologically anomalous after-polarisations, and trigger a dangerous kind of polymorphic ventricular tachyarrhythmia, known as torsade de pointes, which can evolve in ventricular fibrillation and death. The risk associated with the torsadogenic cardiotoxicity of drugs, which prolong the QT interval has been the topic of documents produced by many health authorities, giving important issues about the preclinical and clinical evaluation of cardiac safety. Besides, public and private research laboratories developed several experimental in vitro or in vivo strategies, aimed to an early recognition of the influence of a drug (or of a drugcandidate) on the HERG channel and / or on the cardiac repolarisation process. Also the identification of a possible pharmacophore model, common in all or at least in numerous torsadogenic drugs, could represent a first step for the development of useful in silico approaches, allowing a preliminary indication about the potential torsadogenic property of a given molecule. In this work, we described the electrophysiological basis of torsade de pointes and listed several pharmacological classes of torsadogenic drugs. Among them, we focused our attention on antipsychotics, with an accurate overview on the experimental and clinical reports about their torsadogenic properties. Moreover, a common structural feature exhibited by these drugs, despite of their remarkable chemical differences, is evidenced by a computational approach and is indicated as a possible “facilitating” requirement for their torsadogenic properties. Together with other remarks, coming from different computational studies, the individuation of a satisfactory “toxicophore” model could be greatly useful, for the theoretical prediction of torsadogenic properties of a given chemical moiety and for the design of new drugs devoid of such an undesired and potentially lethal side-effect.
Export Options
About this article
Cite this article as:
Testai L., Bianucci M. A., Massarelli I., Breschi C. M., Martinotti E. and Calderone V., Torsadogenic Cardiotoxicity of Antipsychotic Drugs: a Structural Feature, Potentially Involved in the Interaction with Cardiac HERG Potassium Channels, Current Medicinal Chemistry 2004; 11 (20) . https://dx.doi.org/10.2174/0929867043364351
DOI https://dx.doi.org/10.2174/0929867043364351 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Na+/H+ Exchanger: A Target for Cardiac Therapeutic Intervention
Current Drug Targets - Cardiovascular & Hematological Disorders Immunotherapy Resistance Mechanisms in Renal Cell Cancer
Current Signal Transduction Therapy Successful Radiofrequency Ablation of Atrial Flutter Causing Hemodynamic Instability in a Patient with Recent Myocardial Infarction
Current Cardiology Reviews Extrahepatic Targets and Cellular Reactivity of Drug Metabolites
Current Medicinal Chemistry The Treatment of Behavioral and Psychological Symptoms of Dementia: Weighing Benefits and Risks
Current Alzheimer Research Use of Bipolar Radiofrequency Catheter Ablation in the Treatment of Cardiac Arrhythmias
Current Cardiology Reviews Different Patterns of Statin Use in Patients with Acute Myocardial Infarction
Current Vascular Pharmacology Immune Checkpoint Inhibitors and Cardiac Toxicity: An Emerging Issue
Current Medicinal Chemistry Clinical Management of the Cardiovascular Failure in Sepsis
Current Vascular Pharmacology Mechanical Circulatory Support in Children
Current Cardiology Reviews Pharmacological Therapy in Children with Atrioventricular Reentry: Which Drug?
Current Pharmaceutical Design Emerging Concepts for Myocardial Late Gadolinium Enhancement MRI
Current Cardiology Reviews Novel Penetrating Cations for Targeting Mitochondria
Current Pharmaceutical Design Zacopride Exerts an Antiarrhythmic Effect by Specifically Stimulating the Cardiac Inward Rectifier Potassium Current in Rabbits: Exploration of a New Antiarrhythmic Strategy
Current Pharmaceutical Design Interactive Effect of Combined Exposure to Active and Passive Smoking on Cardiovascular System
Recent Patents on Cardiovascular Drug Discovery Enzyme Replacement Therapy in Fabry Disease: Influence on Cardiac Manifestations
Current Medicinal Chemistry CACNB2: An Emerging Pharmacological Target for Hypertension, Heart Failure, Arrhythmia and Mental Disorders
Current Molecular Pharmacology Association of Viruses in the Development of Cardiovascular Diseases
Current Pharmaceutical Design Current Concepts in the Management of Diabetic Polyneuropathy
Current Diabetes Reviews Recent Patents on Cardiovascular Stem Cells
Recent Patents on Cardiovascular Drug Discovery